CREATION OF THE INFORMATIONAL MODEL OF TOXIC MYOCARDITIS OCCURRED UNDER THE INFLUENCE OF PESTICIDES

2015 ◽  
Vol 8 (2) ◽  
Author(s):  
Sayora Akhmedova
Keyword(s):  
Therapeutic Strategy ◽  
Clinical Symptoms ◽  
Informational Model

Creation of productive knowledge is important whereas on the base of this knowledge we can diagnose morphologic and morphometric properties of vascular stromal tissues of myocardium under toxic myocarditis on the bases of clinical symptoms. Consequence of this is a proper therapeutic strategy that will have a life importance for the patients.

scholarly journals COVID-19 in age-related neurodegenerative diseases: is there a role for vitamin D3 as a possible therapeutic strategy?

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Milena de Barros Viana ◽  
Bárbara dos Anjos Rosário ◽  
Maria de Fátima Santana de Nazaré ◽  
Débora Estadella ◽  
Daniel Araki Ribeiro ◽  
...  
Keyword(s):  
Vitamin D ◽  
Therapeutic Strategy ◽  
Clinical Symptoms ◽  
Large Population ◽  
Mortality Rates ◽  
Vitamin D Supplementation ◽  
World Health ◽  
Age Related ◽  
Alzheimer’S Diseases ◽  
Alzheimer's Diseases

AbstractThe coronavirus disease (COVID-19), identified in Wuhan, China, on December 2019, was declared a pandemic by the World Health Organization, on March, 2020. Since then, efforts have been gathered to describe its clinical course and to determine preventive measures and treatment strategies. Adults older than 65 years of age are more susceptible to serious clinical symptoms and present higher mortality rates. Angiotensin-converting enzyme 2 (ACE2) is a major receptor for some coronavirus infection, including SARS-COV-2, but is also a crucial determinant in anti-inflammation processes during the renin–angiotensin system (RAS) functioning – converting angiotensin II to angiotensin 1–7. The decline in ACE2 expression that occurs with aging has been associated to the higher morbidity and mortality rates in older adults. These observations highlight the importance of investigating the association between COVID-19 and age-related neurodegenerative disorders, i.e., Parkinson’s and Alzheimer’s diseases. A possible option to reduce the risk of COVID-19 is vitamin D supplementation, due to its anti-inflammatory and immune-system-modulating effects. It has also been suggested that vitamin D supplementation plays a role in slowing progression of Parkinson and Alzheimer. The present study is a literature review of articles published on the theme COVID-19, Parkinson and Alzheimer’s diseases, and the role played by vitamin D. PUBMED, MEDLINE, and EMBASE databases were consulted. Results confirm neurodegenerative and neuroinflammatory effects of COVID-19, aggravated in Parkinson’s and Alzheimer’s patients, and the important role of vitamin D as a possible therapeutic strategy. Nevertheless, randomized controlled trials and large population studies are still warranted.

scholarly journals Astragaloside IV Protects Against Diabetic Nephropathy by Inhibiting Pyroptosis Based on NOX4/TXNIP/NLRP3 Pathway

2020 ◽  
Author(s):  
Yudi Zhang ◽  
Chunhe Tao ◽  
Donglin Du ◽  
Chen Xuan ◽  
Wenfu Cao
Keyword(s):  
Diabetic Nephropathy ◽  
Western Blot ◽  
Inflammatory Cytokines ◽  
High Fat Diet ◽  
Therapeutic Strategy ◽  
Clinical Symptoms ◽  
Collagen Iv ◽  
Tunel Staining ◽  
Astragaloside Iv ◽  
Glycation End Products

Background and Purpose: Diabetic nephropathy (DN) is a common and severe chronic complication in diabetes mellitus. The purpose of this study was to explore the effect and mechanism of Astragaloside IV (AS-IV) on renal pyroptosis in DN. Experimental Approach: High-fat diet and a small dose of streptozotocin were used to establish the DN model. Rats were treated with vehicle or AS-IV (20-, 40- and 80-mg/kg/day) or valsartan (30mg/kg/day) by gavage. After 12 weeks, animals were euthanized; samples of urine and blood were collected to examine biochemical indicators, advanced glycation end products (AGEs), inflammatory cytokines; kidney tissues were collected for histological observation, TUNEL staining, AGEs, inflammatory cytokines, redox indicators, western blot, and immunohistochemistry. Key Results: Biochemical results showed that AS-IV could significantly alleviate the degree of clinical symptoms and the levels of blood glucose, HbA1C, TG, MDA, AGEs, Interleukin (IL)-1β, and IL-18 while improving the activity of SOD and the secretion and sensitivity of insulin. Histological examination and TUNEL staining indicated that AS-IV attenuated the damage of tissues and cells in the kidney from DN rats. Western blot results revealed that AS-IV relieved the activation of NOX4/TXNIP/NLRP3 pathway and the expression of collagen IV and fibronectin in DN rats. Immunohistochemistry results showed that AS-IV attenuated collagen IV and fibronectin in the kidney from DN rats. Conclusion and Implications: The NOX4/TXNIP/NLRP3 pathway mediated renal pyroptosis could play a crucial role in kidney damage and DN development in rats. Restoration of renal pyroptosis by AS-IV be a potential therapeutic strategy against DN.

Spinal epidural arteriovenous fistulas associated with progressive myelopathy

2007 ◽  
Vol 6 (6) ◽  
pp. 552-558 ◽  
Author(s):  
Nivaldo Silva ◽  
Anne Christine Januel ◽  
Philippe Tall ◽  
Christophe Cognard
Keyword(s):  
Magnetic Resonance Imaging ◽  
Therapeutic Strategy ◽  
Clinical Symptoms ◽  
Venous Drainage ◽  
Imaging Findings ◽  
Resonance Imaging ◽  
Arterial Access ◽  
Arteriovenous Fistulas ◽  
Progressive Myelopathy ◽  
Spinal Epidural

✓The authors report the cases of four patients who presented with progressive myelopathy (one patient had been asymptomatic for 25 years) due to spinal epidural arteriovenous fistulas (AVFs). Clinical symptoms and magnetic resonance imaging findings were similar to those of dural AVFs. In contrast to dural AVFs, angiography showed that the lesions were fed by multiple vessels and drained in one case in multiple veins. Perimedullary venous drainage was visible in three of the four cases. All fistulas were cured by embolization; arterial access was used in two cases and venous in two. The authors' aim in this paper is to emphasize the differences between dural and epidural AVFs in terms of their physiopathology and angioarchitecture as well as the therapeutic strategy.

Arachnoiditis ossificans of the cauda equina

2002 ◽  
Vol 97 (2) ◽  
pp. 239-243 ◽  
Author(s):  
Alexis Faure ◽  
Mansour Khalfallah ◽  
Brigitte Perrouin-Verbe ◽  
Florence Caillon ◽  
Cedric Deschamps ◽  
...  
Keyword(s):  
Therapeutic Strategy ◽  
Clinical Symptoms ◽  
Treatment Options ◽  
Cauda Equina ◽  
Content Type ◽  
Cerebrospinal Fluid Flow ◽  
Radiological Features ◽  
Cauda Equina Compression ◽  
Histological Data ◽  
Arachnoiditis Ossificans

✓ The authors describe a case of arachnoiditis ossificans (AO) of the cauda equina. The lesion is a rare pathological entity usually confined to the thoracic and high lumbar regions that can cause progressive spinal cord and cauda equina compression, inducing severe neurological deterioration. The authors analyze the clinical symptoms, radiological features, histological data, and treatment options relating to this case and 13 others described in the literature; additionally, they consider the possible mechanisms responsible for ossification of the leptomeninges. Although clustered arachnoidal cells are usually implicated in its pathogenesis, an environment induced by arachnoiditis and disturbed cerebrospinal fluid flow appears to be a more important factor. A therapeutic strategy is proposed for AO for which no effective treatment currently exists.

Impact of the number of changes of therapeutic strategy on improvement in depressed patients. dria study

2011 ◽  
Vol 26 (S2) ◽  
pp. 700-700
Author(s):  
M. Garcia-Toro ◽  
E. Valmisa ◽  
J. Galan ◽  
S. Ros
Keyword(s):  
Therapeutic Strategy ◽  
Clinical Symptoms ◽  
Remission Rate ◽  
Major Depressive ◽  
Pragmatic Clinical Trial ◽  
Remission Rates ◽  
Image Position ◽  
Antidepressant Combination ◽  
Strategy Switch

IntroductionThe STAR*D is a pragmatic clinical trial that showed lower remission rate and higher relapse rate when more strategies were used.[1]Objectives and aimsAssess clinical improvement in symptoms related to depression, anxiety and sleep, based on the number of strategies used.MethodsDescriptive, non-interventional, prospective study including outpatients diagnosed with Major Depressive Disorder (MDD) with sub-optimal response to standard antidepressants. In those patients a change on the therapeutic strategy (switch of antidepressant, combination of antidepressants, augmentation or a combination of previous strategies) had to be considered necessary. Follow-up period was 22–26 weeks.Results364 patients were included by 58 psychiatrists, 336 were analyzed (92.3%) and 315 (86.5%) completed the follow-up.[Difference last visit vs. basal]p < 0.0001 in all measuresConclusionsThe more changes on strategies used the less improvement on clinical symptoms and remission rates.This study has been sponsored by AstraZeneca Farmaceutica Spain, SA.

scholarly journals The effectiveness of a monopreparation containing a combination of ciprofloxacin – ornidazole in the treatment of infectious-inflammatory and dysbiotic vagina diseases

2021 ◽  
pp. 207-215
Author(s):  
V. F. Bezhenar ◽  
O. L. Molchanov ◽  
I. V. Kukes ◽  
A. A. Meznikov ◽  
L. A. Galiullina ◽  
...  
Keyword(s):  
Bacterial Vaginosis ◽  
Therapeutic Strategy ◽  
Clinical Symptoms ◽  
Combination Drug ◽  
Laboratory Findings ◽  
Clinical Symptomatology ◽  
End Of Treatment ◽  
Group 2 ◽  
Comparison Object ◽  
Group 1

Introduction. Infectious inflammatory and dysbiotic diseases of the vagina represent a major concern facing obstetric and gynecological science. Individually, the two most common specific diseases can be distinguished, namely: bacterial vaginosis (BV) and nonspecific vaginitis (NV). The therapeutic strategy for these diseases requires a word of clarification and adjustment.Objective. To conduct a comparative analysis of treatment with the combination drug Orcepol WM (ciprofloxacin (500 mg) and ornidazole (500 mg)) and a combination of monopreparations in a dosage form similar to Orcepol WM.Materials and methods. As a comparison object, we used the method of simultaneous administration by patients of tablet forms of ciprofloxacin and ornidazole as mono-preparations in a dosage of 500 mg similar to Orcepol. The study included 64 patients with diagnoses of “bacterial vaginosis” or “nonspecific vaginitis” or "decompensated mixed vaginal dysbiosis". The average age of the patients was 35.34 ± 5.95 years. The patients were divided into two groups: group 1 (n = 32) received the combination drug Orcepol WM, group 2 (n = 32) received ciprofloxacin and ornidazole with two mono-preparations. The drugs were prescribed as a five-day course, two times a day. The patients were followed up by a doctor during two visits and one remote interview on day 30–45 after the end of treatment (visit 2).Results. In both groups, all patients received a full course of antibacterial therapy. There were no adverse drug reactions. In both groups, there was an improvement in clinical symptoms from the first to the second visit: discomfort, itching, burning, dyspareunia, hyperemia of the mucous membrane against the background of normalization of laboratory findings of the vaginal microbiocenosis condition. At the same time, the best results were higher in group 1. Manifestation of mycotic vaginitis with the development of strong clinical symptomatology on days 3 and 4 of treatment respectively were recorded in 4 (12.5%) patients from group 1 and 7 (21.9%) from group 2. The results of comparative observation showed that the number of relapses after the end of therapy were the same in group 1 (8 out of 32 patients, 25%) and in group 2 (9 out of 32 patients, 28%). The relapse occurred on average day 12 and 17 after the end of therapy, respectively.Сonclusion. Thus, the use of Orcepol WM showed a greater therapeutic efficacy as compared to the use of tablet forms of ciprofloxacin and ornidazole in similar dosages as a single-drug administration, which can be explained by a stronger patients' adherence to the treatment.

Abstract WP429: Therapeutic Strategy For Chronic Subdural Hematoma Associated With Cerebrospinal Fluid Hypovolemia

Stroke ◽  
2013 ◽  
Vol 44 (suppl_1) ◽  
Author(s):  
Takafumi Shimogawa
Keyword(s):  
Cerebrospinal Fluid ◽  
Subdural Hematoma ◽  
Therapeutic Strategy ◽  
Clinical Symptoms ◽  
Traumatic Injury ◽  
Chronic Subdural Hematoma ◽  
Treatment Result ◽  
Hematoma Evacuation ◽  
The Third ◽  
Blood Patch

Chronic subdural hematoma (CSH) with the cerebrospinal fluid (CSF) hypovolemia is often reported, but the therapeutic strategy is not established. We examined the therapeutic strategy and the treatment result for CSH with the CSF hypovolemia that we experienced in our hospital. [Object and method] In 544 patients with CSF hypovolemia during January 2000 to July 2012, 7 cases (1.3%) had CSH bilaterally. About CSF hypovolemia, 5 cases was diagnosed as spontaneous, 1 case as post-traumatic injury, and 1 case as post-traffic injury. We devided them into 3 groups; the first group which performed epidural blood patch (EBP) therapy first, the second group which performed hematoma evacuation for CSH first, and the third group group which performed the hematoma evacuation for CSH and EBP simultaneously. [Result] In the first group included 5 cases, only 1 case of CSH resolved spontaneously, and another 4 cases needed additional hematoma evacuation by aggravation of clinical symptoms. In the second group included 1 case, CSH recurred, and additional EBP therapy and hematoma evacuation were needed. In the third group included 1 case, the improvement of prompt clinical symptoms was obtained and CSH did not recurr. [Conclusion] The treatment for CSH with CSF hypovolemia needs EBP therapy first, however most cases needs an additional hematoma evacuation. If it takes into consideration, it may be better to do the hematoma evacuation and the EBP simultaneouly. In addition, it is necessary to consider a CSF hypovolemia as a cause of a bilateral CSH which relapse after treatment.

scholarly journals Necroptosis: A Novel Pathway in Neuroinflammation

2021 ◽  
Vol 12 ◽  
Author(s):  
Ziyu Yu ◽  
Nan Jiang ◽  
Wenru Su ◽  
Yehong Zhuo
Keyword(s):  
Therapeutic Strategy ◽  
Clinical Symptoms ◽  
Neurological Diseases ◽  
Kinase Domain ◽  
Innate Immune ◽  
Innate Immune Responses ◽  
Interacting Protein ◽  
Microbial Infections ◽  
Activity Dependent ◽  
Necrosis Factor

Neuroinflammation is a complex inflammatory process in the nervous system that is expected to play a significant role in neurological diseases. Necroptosis is a kind of necrosis that triggers innate immune responses by rupturing dead cells and releasing intracellular components; it can be caused by Toll-like receptor (TLR)-3 and TLR-4 agonists, tumor necrosis factor (TNF), certain microbial infections, and T cell receptors. Necroptosis signaling is modulated by receptor-interacting protein kinase (RIPK) 1 when the activity of caspase-8 becomes compromised. Activated death receptors (DRs) cause the activation of RIPK1 and the RIPK1 kinase activity-dependent formation of an RIPK1-RIPK3-mixed lineage kinase domain-like protein (MLKL), which is complex II. RIPK3 phosphorylates MLKL, ultimately leading to necrosis through plasma membrane disruption and cell lysis. Current studies suggest that necroptosis is associated with the pathogenesis of neuroinflammatory diseases, such as Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury. Inhibitors of necroptosis, such as necrostatin-1 (Nec-1) and stable variant of Nec (Nec-1s), have been proven to be effective in many neurological diseases. The purpose of this article is to illuminate the mechanism underlying necroptosis and the important role that necroptosis plays in neuroinflammatory diseases. Overall, this article shows a potential therapeutic strategy in which targeting necroptotic factors may improve the pathological changes and clinical symptoms of neuroinflammatory disorders.

The Potential of Glycyrrhizinate in the Management of COVID-19: A Systematic Review of the Efficacy and Safety of Glycyrrhizin Preparations in the Treatment of SARS and MERS

2020 ◽  
Vol 48 (07) ◽  
pp. 1539-1552
Author(s):  
Huibo Li ◽  
Yang Hu ◽  
Huilin Tang ◽  
Shanshan Li ◽  
Hong Ding ◽  
...  
Keyword(s):  
Therapeutic Strategy ◽  
Randomized Clinical Trials ◽  
Clinical Symptoms ◽  
Descriptive Analysis ◽  
Elevated Serum ◽  
Serum Levels ◽  
Treated Group ◽  
Control Group ◽  
Efficacy And Safety ◽  
Retrospective Cohort Studies

The SARS-CoV-2 outbreak in 2019 highlighted the fact that no specific medications providing effective treatment have been identified and approved. We explored the possibilities for COVID-19 by systematically reviewing evidence on the efficacy and safety of glycyrrhizin preparations for SARS and MERS. Electronic databases were systematically searched from inception to February 2020 for eligible studies that evaluated the efficacy and safety of glycyrrhizin preparations for SARS and MERS. A quantitative analysis or descriptive analysis was applied. Five retrospective cohort studies were included, and NOS scores ranged from 5–7 points. The clinical symptoms of dry cough, chest distress and dyspnoea improved quickly, and elevated serum levels of aminotransferase decreased after compound glycyrrhizin treatment. The SARS-CoV antibody appeared earlier in the treated group than in the control group ([Formula: see text][Formula: see text]d). Compared to that with conventional medications, the average period from peak to 50% improvement of lesions, in terms of X-ray manifestations, was shorter with compound glycyrrhizin treatment ([Formula: see text]2.1[Formula: see text]d), and treatment reduced the dosage ([Formula: see text][Formula: see text]mg/d) and duration of the corticosteroids used, without other serious adverse reactions. Based on the available evidence regarding glycyrrhizin preparations for treating SARS and MERS, we infer that compound glycyrrhizin could be an optional therapeutic strategy for SARS-CoV-2 infections, especially those complicated with liver damage. Further research using well-designed randomized clinical trials (RCTs) is warranted to determine the dosage and duration of use of compound glycyrrhizin and to monitor its specific adverse effects.

scholarly journals Microglial replacement therapy: a potential therapeutic strategy for incurable CSF1R-related leukoencephalopathy

2020 ◽  
Vol 8 (1) ◽  
Author(s):  
Jinming Han ◽  
Heela Sarlus ◽  
Zbigniew K. Wszolek ◽  
Virginija Danylaité Karrenbauer ◽  
Robert A. Harris
Keyword(s):  
Therapeutic Strategy ◽  
Clinical Symptoms ◽  
Gene Mutations ◽  
Research Field ◽  
Hematopoietic Stem ◽  
Axonal Spheroids ◽  
Medical Need ◽  
The Central Nervous System ◽  
Stimulating Factor

AbstractCSF1R-related leukoencephalopathy is an adult-onset leukoencephalopathy with axonal spheroids and pigmented glia caused by colony stimulating factor 1 receptor (CSF1R) gene mutations. The disease has a global distribution and currently has no cure. Individuals with CSF1R-related leukoencephalopathy variably present clinical symptoms including cognitive impairment, progressive neuropsychiatric and motor symptoms. CSF1R is predominantly expressed on microglia within the central nervous system (CNS), and thus CSF1R-related leukoencephalopathy is now classified as a CNS primary microgliopathy. This urgent unmet medical need could potentially be addressed by using microglia-based immunotherapies. With the rapid recent progress in the experimental microglial research field, the replacement of an empty microglial niche following microglial depletion through either conditional genetic approaches or pharmacological therapies (CSF1R inhibitors) is being studied. Furthermore, hematopoietic stem cell transplantation offers an emerging means of exchanging dysfunctional microglia with the aim of reducing brain lesions, relieving clinical symptoms and prolonging the life of patients with CSF1R-related leukoencephalopathy. This review article introduces recent advances in microglial biology and CSF1R-related leukoencephalopathy. Potential therapeutic strategies by replacing microglia in order to improve the quality of life of CSF1R-related leukoencephalopathy patients will be presented.

Sign in / Sign up

Export Citation Format

Share Document